Nephrotic syndrome
Drug research and approvals for nephrotic syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 55 studies of nephrotic syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 2 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 55
- Trials authorized in Canada: 1
- FDA orphan approvals: 2
- EU medicines: 1
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)NCT07710157 · Phase 2 · Medical University Innsbruck · starts Jul 13, 2026
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected…NCT07614477 · Phase 2 · Everest Medicines (China) Co.,Ltd. · starts May 20, 2026
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseNCT07586267 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts May 8, 2026
- A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic…NCT07561957 · Not applicable · St. James's Hospital, Ireland · starts Jan 14, 2026
- SLIT ABS: Study on Patients With Autoimmune PodocytopathyNCT07516964 · Not applicable · Meyer Children's Hospital IRCCS · starts Jun 10, 2025
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseNCT07507201 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts Apr 1, 2026
- A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisNCT07499700 · Phase 2 / Phase 3 · Bio-Thera Solutions · starts Oct 26, 2025
- CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseNCT07305116 · Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts Dec 1, 2025
Approved 16
- PrednisoneGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- CyclophosphamideDNA inhibitor
- BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- SpironolactoneMineralocorticoid receptor antagonist
- TriamtereneAmiloride-sensitive sodium channel, ENaC blocker
- Ethacrynic acidSodium-(potassium)-chloride cotransporter 2 inhibitor
- ChlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- Betamethasone acetateGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- Methylprednisolone acetateGlucocorticoid receptor agonist
- Prednisolone phosphoric acidGlucocorticoid receptor agonist
- CholestyramineBile acids sequestering agent
Phase 3 10
- RituximabB-lymphocyte antigen CD20 binding agent
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- Mycophenolic acidInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- LevamisoleNicotinic acetylcholine receptor alpha subunit agonist
- Phenol
- CorticotropinMelanocortin receptor 2 agonist
- PentoxifyllineAdenosine A2 receptor antagonist
- MizoribineInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Telitacicept
Phase 2 10
- OfatumumabB-lymphocyte antigen CD20 binding agent
- AldesleukinInterleukin-2 receptor agonist
- Enoxaparin sodiumAntithrombin-III activator
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- AtorvastatinHMG-CoA reductase inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor
- Pirfenidone
- AlirocumabSubtilisin/kexin type 9 inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
Phase 1 or earlier 1
- ApixabanCoagulation factor X inhibitor
How its trials ended
175 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 33 whose ending is known, 33% met their primary endpoint, 9% missed it and 58% stopped early.
- Ongoing5934%
- Completed, result not reported5330%
- Status unknown3017%
- Met its primary endpoint116%
- Stopped: other or unclear116%
- Missed its primary endpoint32%
- Stopped: lack of efficacy32%
- Stopped: enrollment or feasibility32%
- Stopped: sponsor or business decision21%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Sep 6, 2023 | Second line immune suppressive drugs in frequently relapsing childhood nephrotic syndrome: a 3-arm randomized trial comparing cyclophosphamide, tacrolimus &…Cyclophosphamide / Mycophenolate / Tacrolimus | Governors of The University of Calgary | Pending |
| Sep 25, 2026 | GazyvaTo reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent… | Genentech, Inc. | Approved |
| Apr 13, 2026 | FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without… | Travere Therapeutics, Inc. | Approved |
| Jul 20, 2022 | Pioglitazone hydrochlorideTreatment of childhood onset idiopathic nephrotic syndrome (defined as steroid dependent or frequently relapsing NS). | NephKey Therapeutics, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 26, 2023 | QaialdoSpironolactone | Lipomed GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA